Managing R/R DLBCL in 2026: Expert Perspectives from the Sobi Symposium at EHA

Support: This symposium recording was initiated, organised, and funded by Sobi.

Disclaimer: This content is intended for healthcare professionals only. The speakers received honoraria for their participation in the symposium.

This Sobi symposium, recorded live at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, brings together four leading global experts to examine the evolving landscape of relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). The faculty discusses treatment advances and ongoing gaps, drawing on real-world data, clinical cases, and the latest research to offer practical perspectives for daily haematology practice.

Topics covered:

• Current treatment challenges and unmet needs in R/R DLBCL 
• Real-world data and patient cases
• Sequencing strategies after first relapse 
• Current clinical data of emerging therapies and ongoing research 
• Practical takeaways for managing R/R DLBCL in 2026 

Timestamps:

• Pier Luigi Zinzani (Introduction) – 00:00:00 to 00:02:43:20
• Anna Sureda – 00:02:47:06 to 00:14:30:20
• Andrew Davies – 00:14:50:07 to 00:31:29:06
• Enrico Derenzini – 00:31:52:19 to 00:46:57:00
• Pier Luigi Zinzani – 00:47:036:10 to 01:05:53

1. University Hospital Southampton, UK
2. University of Barcelona, Spain
3. University of Bologna, Italy
4. University of Milan, Italy

Zinzani has received consulting fees and honoraria from BMS, BeiGene, Celltrion, Eli Lilly, EUSA Pharma, Gilead, Incyte, Janssen-Cilag, Kyowa Kirin, MSD, Novartis, Roche, Servier, Takeda, and TG Therapeutics; and served on scientific advisory boards for ADC Therapeutics, BeiGene, BMS, Celltrion, Eli Lilly, EUSA Pharma, Gilead, Incyte, Janssen-Cilag, Kyowa Kirin, MSD, Novartis, Roche, Sandoz, Secura Bio, Servier, Takeda, and TG Therapeutics. 

Sureda has received research support as a PI from Takeda; consulting fees and honoraria from AbbVie, Amgen, BMS/Celgene, Genmab, Gilead Kite, Janssen, Jazz Pharmaceuticals, MSD, Novartis, Roche, Sanofi, and Takeda; and served on a scientific advisory board for Takeda. 

Davies has received research support as a PI from Acerta Pharma/AstraZeneca, Celgene (a Bristol Myers Squibb Company), Janssen, Kite (a Gilead company), MSD and Roche; consulting fees and honoraria from AbbVie, Acerta Pharma/AstraZeneca, Celgene (a Bristol Myers Squibb Company), Janssen, JW Therapeutics, Kite (a Gilead company), Roche, and Sobi; and served on scientific advisory boards for AbbVie, Celgene (a Bristol Myers Squibb Company), Genmab, Incyte, Kite (a Gilead company), Prelude, Roche, SERB, and Sobi. 

Derenzini has received research support as a PI from ADC Therapeutics and Takeda; consulting feed and honoraria from AbbVie, AstraZeneca, J&J, and Regeneron; and served on scientific advisory boards for AbbVie, AstraZeneca, BeiGene, and Roche. 

NP 51195 | Date of preparation: June 2026
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
© 2026 Swedish Orphan Biovitrum AB (publ) -All rights reserved
SE-112 76 Stockholm, Sweden